Archives
-
Cell Lysis Buffer for WB and IP in CAF Studies
2026-09-07
Translate cancer-associated fibroblast signaling into reliable Western blot, immunoprecipitation, and co-IP workflows with a non-denaturing extraction system. This guide shows how K1123 supports phosphorylation preservation, protein-interaction studies, and troubleshooting across prostate cancer and tumor-microenvironment samples.
-
L. plantarum P101 Activates AMPK in Alcoholic Steatosis
2026-09-07
A 2025 mouse study shows that Lactiplantibacillus plantarum P101 reduced alcohol-induced hepatic lipid accumulation while activating AMPK, with associated changes in gut microbiota and serum metabolites. Pharmacological AMPK inhibition weakened these benefits, supporting a mechanistic role for AMPK while indicating that microbiota and metabolite correlations require further causal testing.
-
NMDA Workflows for Excitotoxicity Research
2026-09-05
NMDA provides a controlled way to activate NMDA receptors and connect early calcium loading with later oxidative stress, ferroptosis, and retinal ganglion cell injury. This practical workflow translates the BMP4-GPX4 glaucoma findings into assay choices for excitotoxicity research and neurodegenerative disease models.
-
Deferasirox in Iron-Dependent Cell Death Assays
2026-09-04
Deferasirox is an oral iron chelator that can be used as a mechanistic probe for iron-dependent stress, lysosomal dysfunction, and metabolic vulnerability. This workflow connects iron handling with the TCF25–V-ATPase response to glucose starvation while separating validated findings from testable cancer-research hypotheses.
-
Primidone and CYP19: Evidence from Antiepileptic Screening
2026-09-04
Jacobsen, Halling-Sørensen, and Birkved evaluated 12 antiepileptic drugs for inhibition of human aromatase CYP19 and found that Primidone, also known as Mysoline, did not inhibit the enzyme in their microsomal assay. The study provides a useful framework for separating CYP19-related endocrine mechanisms from other pharmacological activities and for interpreting combination-therapy risks.
-
PR-619: Deubiquitylating Enzymes Inhibitor Workflows
2026-09-03
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for tracking ubiquitin accumulation without directly blocking proteasomal catalysis. This guide translates its chemistry into practical workflows for ubiquitination pathway research, autophagy activation assays, cancer biology research, and neurodegenerative disease models.
-
DiscoveryProbe Natural Product Library Plus: Assay Design
2026-09-03
Discover how the DiscoveryProbe Natural Product Library Plus can support evidence-driven natural product screening for drug discovery. This guide translates CpAdhE study findings into practical HTS, HCS, and orthogonal validation decisions.
-
2X Taq PCR Master Mix for Plant Virus Workflows
2026-09-02
Connect field-image disease screening with practical confirmatory PCR using a ready-to-use Taq formulation. The integrated loading dye simplifies gel analysis, while Taq-generated adenine overhangs support downstream TA cloning of selected amplicons.
-
Protein A/G Magnetic Beads for TNBC Mechanism
2026-09-02
Protein A/G Magnetic Beads can help convert the IGF2BP3–FZD1/7 discovery into a rigorous, layered assay strategy. This guide explains how to distinguish RNA binding, protein complex formation, and chromatin effects while reducing background in TNBC studies.
-
Optimized GBA1 mRNA for Gaucher Disease Therapy
2026-09-01
The reference study develops an optimized human GBA1 mRNA platform by systematically modifying untranslated regions, codon usage, and poly(A) tails. The resulting mRNA improved glucocerebrosidase expression and persistence, restored lysosomal phenotypes in GBA1-deficient cells, and produced detectable enzyme activity in mouse liver and spleen after lipid nanoparticle delivery.
-
Sulfo-NHS-Biotin for Reliable Cell Assays
2026-09-01
This scenario-based guide explains how Sulfo-NHS-Biotin (SKU A8001) can add an orthogonal cell-surface labeling and affinity-capture layer to viability, proliferation, and cytotoxicity workflows. It also separates validated product specifications from practical recommendations so researchers can make defensible decisions about protocol design, interpretation, and supplier selection.
-
SEC-seq Reveals VEGF-A-Secreting MSC States
2026-08-31
The reference study introduces secretion encoded single-cell sequencing (SEC-seq), a nanovial-based workflow that measures VEGF-A secretion and transcriptomes from individual mesenchymal stromal cells. It shows that secretion is heterogeneous and only weakly predicted by VEGFA mRNA, identifying a distinct high-secretion subpopulation relevant to cell therapy and regenerative medicine research.
-
ML216 and the Translational Logic of BLM Inhibition
2026-08-31
ML216 is a selective BLM helicase inhibitor that connects DNA repair biology, synthetic-lethality research, and translational oncology. This article explains how to interpret its mechanistic evidence, design rigorous validation studies, and distinguish BLM-focused findings from the separate WRN–MSI vulnerability reported in colorectal cancer.
-
Optimized GBA1 mRNA for Gaucher Disease Therapy
2026-08-30
A 2026 study engineered human GBA1 mRNA through coordinated optimization of untranslated regions, codon usage, and poly(A) tails, producing sustained glucocerebrosidase expression and lysosomal functional rescue in cellular models. Lipid nanoparticle delivery generated detectable enzyme activity in mouse liver and spleen, supporting mRNA-LNP development while leaving disease-model efficacy, biodistribution, and neurological access unresolved.
-
Jasplakinolide: Designing Better Actin Assays
2026-08-29
Jasplakinolide is an actin polymerization inducer whose effects combine filament assembly with F-actin stabilization. This guide presents an assay-centered framework for separating biochemical, structural, and antiproliferative outcomes while adapting chemical-genetic reasoning from plant signaling research.